Loading...
Market
Will Moldova report adverse effects from PBGENE-HBV trial by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official statements from Moldova's health authorities or Precision BioSciences
Story
Moldova Approves Precision BioSciences' PBGENE-HBV Gene Editing Study for Chronic Hepatitis B
Oct 24, 2024, 12:51 PM
Moldova has approved its first gene editing study for human trials targeting Hepatitis B virus (HBV). Precision BioSciences has received the necessary approval to initiate the PBGENE-HBV clinical trial, which aims to test the effectiveness of gene editing in removing persistent viral DNA in patients with chronic HBV. This marks a significant step in gene therapy, as it will be the first human trial using such technology to address this viral infection.
View original story
Similar markets
No significant contamination found • 25%
Contamination confirmed, no recall • 25%
Contamination confirmed, recall issued • 25%
Investigation inconclusive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
Yes • 50%
No • 50%
